Leptomeningeal Carcinomatosis

Note: the content in these publications is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

A Novel Therapeutic Approach for Leptomeningeal Metastases

Duke University School of Medicine/Minnetronix Neuro

Mayo Clinic Neuroscience and Oncology Innovation Summit 2017 –
December 14-16, 2017 – Orlando, FL

Leptomeningeal Metastases (LM) occurs when primary tumor cells metastasize, invade the subarachnoid space, and spread throughout the cerebrospinal fluid (CSF). As novel cancer therapies extend survival, LM has become increasingly prevalent, with approximately 110,000 diagnoses per year in the U.S.1 Despite advances in targeted radiation and chemotherapy, survival averages 3-6 months after LM diagnosis.2,3 Reducing tumor burden is the primary goal to extend survival and quality of life. We propose an intrathecal catheter-based extracorporeal filtration system (NeurapheresisTM therapy) as an alternative mechanical intervention for the filtration of tumor cells and distribution of chemotherapeutics in the CSF. Here, we demonstrate the ability of our system to reduce VX2 carcinoma cells in vitro.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number R41CA206742 (100% support, $224,970)

Leptomeningeal disease: current diagnostic and therapeutic strategies

Gautam Nayar, Tiffany Ejikeme, et al
Oncotarget – August 16, 2017

Abstract: Leptomeningeal disease has become increasingly prevalent as novel therapeutic interventions extend the survival of cancer patients. Although a majority of leptomeningeal spread occurs secondary to breast cancer, lung cancer, and melanoma, a wide variety of malignancies have been reported as primary sources. Symptoms on presentation are equally diverse, often involving a combination of neurological deficits with the possibility of obstructive hydrocephalus. Diagnosis is definitively made via cerebrospinal fluid cytology for malignant cells, but neuro-imaging with high quality T1-weighted magnetic resonance imaging can aid diagnosis and localization. While leptomeningeal disease is still a terminal, late-stage complication, a variety of treatment modalities, such as intrathecal chemotherapeutics and radiation therapy, have improved median survival from 4–6 weeks to 3–6 months. Positive prognosticative factors for survival include younger age, high performance scores, and controlled systemic disease. In looking to the future, diagnostics that improve early detection and chemotherapeutics tailored to the primary malignancy will likely be the most significant advances in improving survival.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number R41CA206742 (100% support, $224,970)

Contact NRC for more information about our programs or participation inquiries, contact us.
CAUTION – Investigational Device, limited by Federal Law to Investigational Use.
Minnetronix is a registered trademark, and Neurapheresis is a trademark of Minnetronix, Inc.
©Minnetronix, Inc. All rights reserved.